Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 5/20 | 1.00 |
| ▸ | PI4KA | P42356 | 4/20 | 1.00 |
| ▸ | PI4K2B | Q8TCG2 | 4/20 | 1.00 |
| ▸ | PI4K2A | Q9BTU6 | 4/20 | 1.00 |
| ▸ | PI4KB | Q9UBF8 | 4/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 3/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.94 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.79 |
| ▸ | BLM | P54132 | 2/20 | 0.79 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.79 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.79 |
| ▸ | THPO | P40225 | 1/20 | 0.79 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.79 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.79 |
| ▸ | TP53 | P04637 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3245641 | 0.98 | ADORA2A (1.00) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL21435666 | 0.97 | ADORA2A (1.00) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL28984637 | 0.93 | ADORA2A (1.00) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| Methyl Alcohol SCHEMBL10438261 | 0.92 | ADORA2A (0.91) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL20536490 | 0.89 | CYP1A2 (1.00) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL3712758 | 0.86 | ADORA2A (0.79) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| Hydrochloric Acid SCHEMBL15310347 | 0.84 | ADORA2A (0.77) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL17546014 | 0.84 | ADORA2A (0.72) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL9470633 | 0.81 | ADORA2A (0.71) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL5188585 | 0.80 | ADORA2A (0.75) | ADORA2API4KAPI4K2BPI4K2API4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210290623-A1 | METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS | DALCOR PHARMA UK LTD., LEATHERHEAD, ZUG BRANCH (CH) | 2021-09-23 | — | — | US | claimed |
| EP-3833336-A1 | METHODS FOR DELAYING OCCURRENCE OF NEW-ONSET TYPE 2 DIABETES AND FOR SLOWING PROGRESSION OF AND TREATING TYPE 2 DIABETES | DalCor Pharma UK Ltd Leatherhead, Zug Branch (CH) | 2021-06-16 | — | — | EP | claimed |
| CN-112888432-A | Methods for delaying the onset of new onset type 2 diabetes and for slowing the progression of type 2 diabetes and treating type 2 diabetes | 英国达科(莱得海德)制药有限公司-楚歌分公司 | 2021-06-01 | — | — | CN | claimed |
| US-10898516-B2 | Compositions and methods of treating diabetic retinopathy | CASE WESTERN UNIVERSITY (US) | 2021-01-26 | — | — | US | claimed |
| US-10568851-B2 | Compounds and methods of treating ocular disorders | CASE WESTERN RESERVE UNIVERSITY (US) | 2020-02-25 | — | — | US | claimed |
| EP-3609521-A1 | TARGETING CELL TROPISM RECEPTORS TO INHIBIT CYTOMEGALOVIRUS INFECTION | University of Massachusetts (US) | 2020-02-19 | — | — | EP | claimed |
| WO-2020030814-A1 | METHODS FOR DELAYING OCCURRENCE OF NEW-ONSET TYPE 2 DIABETES AND FOR SLOWING PROGRESSION OF AND TREATING TYPE 2 DIABETES | DALCOR PHARMA UK LTD., LEATHERHEAD, ZUG BRANCH (CH) | 2020-02-13 | — | — | WO | claimed |
| US-20190255102-A1 | COMPOSITIONS AND METHODS OF TREATING DIABETIC RETINOPATHY | CASE WESTERN UNIVERSITY | 2019-08-22 | — | — | US | claimed |
| US-10272106-B2 | Compositions and methods of treating diabetic retinopathy | CASE WESTERN RESERVE UNIVERSITY (US) | 2019-04-30 | — | — | US | claimed |
| US-20190070178-A1 | METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS | DALCOR PHARMA UK LTD., LEATHERHEAD, ZUG BRANCH (CH) | 2019-03-07 | — | — | US | claimed |
| EP-3151818-A1 | COMPOSITIONS AND METHODS OF TREATING DIABETIC RETINOPATHY | Case Western Reserve University (US) | 2017-04-12 | — | — | EP | claimed |
| WO-2015187942-A1 | COMPOSITIONS AND METHODS OF TREATING DIABETIC RETINOPATHY | CASE WESTERN RESERVE UNIVERSITY (US) | 2015-12-10 | — | — | WO | claimed |
| US-20140235562-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | CASE WESTERN RESERVE UNIVERSITY | 2014-08-21 | — | — | US | claimed |
| WO-2013063269-A2 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | CASE WESTERN RESERVE UNIVERSITY (US) | 2013-05-02 | — | — | WO | claimed |
| US-7700352-B2 | Composition for culturing mouse pluripotent stem cells | RIKEN (JP) | 2010-04-20 | — | — | US | claimed |
| US-20090264383-A1 | Inhibitor of Adenylyl Cyclase for Treating a Disorder of the Circadian Rhythm | MEDICAL RESEARCH COUNCIL (GB) | 2009-10-22 | — | — | US | claimed |
| EP-2023921-A1 | INHIBITOR OF ADENYLYL CYCLASE FOR TREATING A DISORDER OF THE CIRCADIAN RHYTHM | Medical Research Council (GB) | 2009-02-18 | — | — | EP | claimed |
| WO-2007135387-A1 | INHIBITOR OF ADENYLYL CYCLASE FOR TREATING A DISORDER OF THE CIRCADIAN RHYTHM | MEDICAL RESEARCH COUNCIL (GB) | 2007-11-29 | — | — | WO | claimed |
| US-20060127370-A1 | Composition for culturing multipotent stem cells and utilization of the same | RIKEN (JP) | 2006-06-15 | — | — | US | claimed |
| EP-1557461-A1 | COMPOSITION FOR CULTURING MULTIPOTENT STEM CELLS AND UTILIZATION OF THE SAME | RIKEN (JP) | 2005-07-27 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235562-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | ALDH1A2, TXNRD2, TXNRD1 | ADORA2A 1522/4885PI4KA 1676/4885PI4K2B 1342/4885 |
| US-20190255102-A1 | COMPOSITIONS AND METHODS OF TREATING DIABETIC RETINOPATHY | GPR119, ARRB1, GRK1 | ADORA2A 307/4885PI4KA 1708/4885PI4K2B 1647/4885 |
| US-10272106-B2 | Compositions and methods of treating diabetic retinopathy | GPR119, ARRB1, GRK1 | ADORA2A 307/4885PI4KA 1708/4885PI4K2B 1647/4885 |
| US-10568851-B2 | Compounds and methods of treating ocular disorders | ALDH1A2, TXNRD2, TXNRD1 | ADORA2A 1522/4885PI4KA 1676/4885PI4K2B 1342/4885 |
| US-20190070178-A1 | METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS | HMGCR, PCSK9, FABP3 | ADORA2A 605/4885PI4KA 3777/4885PI4K2B 3928/4885 |
| US-20210290623-A1 | METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS | HMGCR, PCSK9, FABP3 | ADORA2A 605/4885PI4KA 3777/4885PI4K2B 3928/4885 |
| US-10898516-B2 | Compositions and methods of treating diabetic retinopathy | GPR119, ARRB1, GRK1 | ADORA2A 307/4885PI4KA 1708/4885PI4K2B 1647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.